임상 단계의 치료제 발굴 및 개발 기업인 Compugen Ltd.는 이스라엘, 미국, 유럽에서 치료제 및 제품 후보 물질의 연구, 개발, 상업화에 주력하고 있습니다. 동사의 파이프라인에는 항-PVRIG 항체를 포함하는 면역항암 프로그램인 COM701과 치료용 항-TIGIT 항체인 COM902가 포함되어 있습니다. 이들은 임상 1상 시험 단계에 있으며, 단독 요법 및 PVRIG/PD-1, PVRIG/TIGIT 병용 요법, 그리고 PVRIG/PD-1/TIGIT 삼중 차단 요법으로 고형암 치료를 위해 평가되고 있습니다. 또한, ILDR2
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.
